← Back to Search

Corticosteroid

Dexamethasone for Childhood Asthma (iSTAT PICU Trial)

Phase 4
Waitlist Available
Led By Anthony A Sochet, MD, MS
Research Sponsored by Johns Hopkins All Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Inclusion criteria are children 5 to 17 years of age with primary admission diagnoses of acute asthma exacerbation or status asthmaticus admitted to the PICU
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment through hospital discharge, up to 1 week
Awards & highlights

iSTAT PICU Trial Summary

This study is evaluating whether a steroid medication is more effective than another in treating children with asthma.

Eligible Conditions
  • Childhood Asthma

iSTAT PICU Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

iSTAT PICU Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment through hospital discharge, up to 1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment through hospital discharge, up to 1 week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Length of Stay
Secondary outcome measures
Duration of Continuous Nebulized Albuterol
Other outcome measures
Corticosteroid-related Adverse Events
Number of Participants Receiving an Adjunctive Asthma Therapy

Side effects data

From 2013 Phase 4 trial • 122 Patients • NCT01474915
2%
Deep Vein Thrombosis
2%
Cerebrospinal fluid leak
2%
Fever
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ondansetron
Aprepitant

iSTAT PICU Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Dexamethasone ArmExperimental Treatment1 Intervention
Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
Group II: Methylprednisolone ArmActive Control1 Intervention
Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
FDA approved

Find a Location

Who is running the clinical trial?

Johns Hopkins All Children's HospitalLead Sponsor
42 Previous Clinical Trials
5,007,151 Total Patients Enrolled
Anthony A Sochet, MD, MSPrincipal InvestigatorJohns Hopkins All Children's Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~16 spots leftby Mar 2025